Abstract
Background
Osteoradionecrosis (ORN) of the jaws remains one of the most debilitating complications
of radiotherapy (RT) in head and neck cancer (HNC) patients. Liquid pentoxifylline
and vitamin E (PVe) presents an alternative formulation to tablets for patients presenting
with dysphagia or enteric feeding
Objective
The purpose of this study was to assess the clinical outcomes for the use of a liquid
formulation of PVe for both established ORN and as a prophylaxis to avoid its occurrence
following dental extractions. A secondary objective was to determine patient-reported
side effects in relation to the liquid formulation of PVe
Study design
Clinical records of 111 HNC patients who were prescribed liquid PVe were reviewed
retrospectively (66 with established ORN and 45 as a prophylaxis prior to an invasive
dental procedure)
Results
In established ORN, 44% healed and 41% were stable. In the prophylaxis group, 96%
of surgical sites healed completely with 4% (n = 2) developing ORN.Most patients (89%)
were able to tolerate liquid PVe. Of the 11% (n =12) who were unable to tolerate this
regime, the most common reported side effect was gastric irritation (n=5/12) while
dizziness, malaise and bleeding was reported by no more than one patient
Conclusions
This retrospective review suggests that liquid PVe is efficacious for both established
ORN and as a prophylaxis. Side effects reported were similar to those recognised for
the tablet formulation.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Accepted:
February 19,
2023
Received in revised form:
February 8,
2023
Received:
January 17,
2023
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
